Halozyme Therapeutics, Inc. (BMV:HALO)
Mexico
· Delayed Price · Currency is MXN 1,183.97
0.00 (0.00%)
At close: Mar 5, 2026
Halozyme Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,397 | 1,015 | 829.25 | 660.12 | 443.31 | Upgrade
|
| Revenue Growth (YoY) | 37.55% | 22.44% | 25.62% | 48.91% | 65.66% | Upgrade
|
| Cost of Revenue | 310.26 | 238.47 | 268.72 | 205.91 | 117.09 | Upgrade
|
| Gross Profit | 1,086 | 776.86 | 560.53 | 454.21 | 326.23 | Upgrade
|
| Selling, General & Admin | 193.39 | 154.34 | 149.18 | 121.63 | 50.32 | Upgrade
|
| Amortization of Goodwill & Intangibles | 76.66 | 71.05 | 73.77 | 43.15 | - | Upgrade
|
| Operating Expenses | 270.05 | 225.38 | 222.96 | 164.77 | 50.32 | Upgrade
|
| Operating Income | 816.29 | 551.48 | 337.57 | 289.43 | 275.9 | Upgrade
|
| Interest Expense | -18.13 | -18.1 | -18.76 | -16.95 | -7.53 | Upgrade
|
| Interest & Investment Income | 18.01 | 12.83 | 10 | 3.88 | 3.36 | Upgrade
|
| EBT Excluding Unusual Items | 816.17 | 546.21 | 328.81 | 276.36 | 271.74 | Upgrade
|
| Merger & Restructuring Charges | -13.7 | - | - | -21.9 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.47 | 10.93 | 6.32 | -2.83 | -2.26 | Upgrade
|
| Asset Writedown | -48.7 | - | - | - | - | Upgrade
|
| Other Unusual Items | -5.48 | - | 13.2 | -2.71 | -20.96 | Upgrade
|
| Pretax Income | 466.88 | 557.13 | 348.33 | 248.92 | 248.52 | Upgrade
|
| Income Tax Expense | 149.99 | 113.04 | 66.74 | 46.79 | -154.19 | Upgrade
|
| Net Income | 316.89 | 444.09 | 281.59 | 202.13 | 402.71 | Upgrade
|
| Net Income to Common | 316.89 | 444.09 | 281.59 | 202.13 | 402.71 | Upgrade
|
| Net Income Growth | -28.64% | 57.71% | 39.31% | -49.81% | 211.97% | Upgrade
|
| Shares Outstanding (Basic) | 120 | 127 | 132 | 137 | 141 | Upgrade
|
| Shares Outstanding (Diluted) | 124 | 129 | 134 | 141 | 147 | Upgrade
|
| Shares Change (YoY) | -4.26% | -3.56% | -4.56% | -4.21% | 3.77% | Upgrade
|
| EPS (Basic) | 2.64 | 3.50 | 2.13 | 1.48 | 2.86 | Upgrade
|
| EPS (Diluted) | 2.56 | 3.43 | 2.10 | 1.44 | 2.74 | Upgrade
|
| EPS Growth | -25.36% | 63.33% | 45.83% | -47.45% | 201.10% | Upgrade
|
| Free Cash Flow | 644.59 | 468.37 | 373.28 | 235.3 | 297.98 | Upgrade
|
| Free Cash Flow Per Share | 5.20 | 3.62 | 2.78 | 1.67 | 2.03 | Upgrade
|
| Gross Margin | 77.78% | 76.51% | 67.59% | 68.81% | 73.59% | Upgrade
|
| Operating Margin | 58.45% | 54.32% | 40.71% | 43.84% | 62.24% | Upgrade
|
| Profit Margin | 22.69% | 43.74% | 33.96% | 30.62% | 90.84% | Upgrade
|
| Free Cash Flow Margin | 46.15% | 46.13% | 45.01% | 35.64% | 67.22% | Upgrade
|
| EBITDA | 897.84 | 627.09 | 416.93 | 336.07 | 277.3 | Upgrade
|
| EBITDA Margin | 64.29% | 61.76% | 50.28% | 50.91% | 62.55% | Upgrade
|
| D&A For EBITDA | 81.55 | 75.61 | 79.36 | 46.64 | 1.4 | Upgrade
|
| EBIT | 816.29 | 551.48 | 337.57 | 289.43 | 275.9 | Upgrade
|
| EBIT Margin | 58.45% | 54.32% | 40.71% | 43.84% | 62.24% | Upgrade
|
| Effective Tax Rate | 32.13% | 20.29% | 19.16% | 18.80% | - | Upgrade
|
| Revenue as Reported | 1,397 | 1,015 | 829.25 | 660.12 | 443.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.